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Background: Brown propolis is the major type of propolis found in Cuba; its principal component is nemorosone,
the major constituent of Clusia rosea floral resins. Nemorosone has received increasing attention due to its strong
in vitro anti-cancer action. The citotoxicity of nemorosone in several human cancer cell lines has been reported and
correlated to the direct action it has on the estrogen receptor (ER). Breast cancer can be treated with agents that
target estrogen-mediated signaling, such as antiestrogens. Phytoestrogen can mimic or modulate the actions of
endogenous estrogens and the treatment of breast cancer with phytoestrogens may be a valid strategy, since they
have shown anti-cancer activity.
Methods: The aim of the present investigation was to assess the capacity of nemorosone to interact with ERs, by
Recombinant Yeast Assay (RYA) and E-screen assays, and to determine by comet assay, if the compound causes
DNA-damaging in tumoral and non-tumoral breast cells.
Results: Nemorosone did not present estrogenic activity, however, it inhibited the 17-β-estradiol (E2) action when
either of both methods was used, showing their antiestrogenicity. The DNA damage induced by the
benzophenone in cancer and normal breast cells presented negative results.
Conclusion: These findings suggest that nemorosone may have therapeutic application in the treatment of
breast cancer.
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The Clusia genus includes about 300 species that occur
throughout the interneotropical realm, from southern
USA and Mexico to southern Brazil and Bolivia [1].
Many Clusia species produce resiniferous waxes in
staminate, and/or pistillate flowers, providing material
for honey bees nest construction [2]. Production of these
resins is a significant pollinator attractant [1].
The bees collect floral resins from the Clusia genus in
order to produce propolis [2,3] that is widely used in* Correspondence: flaviabiomed@yahoo.com.br
1UNESP- Univ. Estadual Paulista, Faculty of Pharmaceutical Sciencies of
Araraquara-Department of Biological Sciences, Rodovia Araraquara-Jaú, Km 1,
14801-902 Araraquara, São Paulo, Brazil
Full list of author information is available at the end of the article
© 2013 Camargo et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the ortraditional medicine and is reported to have a broad
spectrum of pharmacological properties [4]. Propolis has
recently gained popularity as a health food supplement
and is used extensively in foods and beverages in various
parts of the world; this compound has been the subject of
many studies due to its antibacterial, antifungal, antiviral
and hepatoprotective activity. Water or alcohol-soluble
propolis and its many compounds have been used in the
treatment of inflammation, for immuno-stimulation and
as an anticancer agent [5]. Its chemical composition is
qualitatively and quantitatively variable, depending on the
vegetation in the area from which it was collected [6].
Brown propolis is the major type of propolis in Cuba;
its chemical composition is exclusive and the principalal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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major constituent of Clusia rosea floral resins [8,9].
Nemorosone is responsible for the antimicrobial activ-
ity of Clusia spp. resin and propolis [10]. This com-
pound is a natural-occurring polycyclic polyprenylated
acylphloroglucinols and has received increasing attention
due to its strong in vitro anti-cancer action; [11,12]. The
cytotoxicity of nemorosone to several human cancer cell
lines has been reported [2] and it has been shown that an
ethanol extract of brown cuban propolis exerts a signifi-
cant cytotoxic activity against breast cancer cells (MCF-7),
which is correlated to a direct action on the estrogen
receptor (ER) [7,9].
Estrogens have been recognized as the main hormones
that stimulate the growth and development of breast
cancers. Their activities are mediated by two main
isoforms of intracellular ERs: ERα and ERβ [13,14]. ERα
is expressed in about 75% of diagnosed breast tumors [7]
and can thus be treated with agents targeting estrogen-
mediated signaling, such as antiestrogens [15,16] . The
introduction of adjuvant systemic therapy led to a signifi-
cant improvement in post-surgical survival and a reduction
in disease relapse, especially in women with early breast
cancer and with positive ER tumors, who may receive
endocrine therapy alone or in combination with cytotoxic
therapy [17].Figure 1 Nemorosone.Phytoestrogen is any plant substance or metabolite that
induces biological responses in vertebrates and can mimic
or modulate the actions of endogenous estrogens [18].
Breast cancer treatment done with phytoestrogens may
be a valid strategy; they are widely distributed in the
diet and herbs and have shown anti-cancer activity via
mechanisms, which include ER modulation, aromatase
inhibition and anti-angiogenesis [19].
Recently, in previous studies, nemorosone presented no
estrogenic activity in the RYA and no mutagenic activity
in the Ames Test. On the other hand, the compound
presented antimutagenic activity, reducing DNA damages
induced by the antitumoral mytomicin C [20]. In the order
to complement the above results, in view of the outstanding
antiproliferative potential of nemorosone and the small
number of studies published on its mechanisms of action,
the aim of the present investigation was to assess the
possible capacity of benzophenone to interact with ERs,
by RYA and E-screen assays, and to determine, by
comet assay, if the compound causes DNA-damage in
tumoral and non-tumoral breast cells.
Methods
Plant material
Flowers of Clusia rosea Jacq. (Gutiferae), were collected in
Havana (Cuba) in September 2009 and identified by Dr.
Victor Fuentes Fiallo. A voucher specimen (No. 9576) was
deposited in the Herbarium of La Estacion Experimental
de Plantas Medicinales de Guira de Melena. Nemorosone
was extracted from the floral resin of C. rosea and isolated
as previously reported by Cuesta-Rubio et al. [8].
Nemorosone was crystallized from floral resin of C.
rosea, employing a mixture of EtOH-H2O. The product
was subjected to vacuum liquid chromatography (VLC)
on silica gel with C6H12-EtOAc (3:1) to purify it to
homogeneity. It was identified by 1D- and 2D-NMR ex-
periments, and its purity was verified by HPLC-DAD and
HPLC-MS. The structure of nemorosone (C33H42O4) is a




The crystallization process yielded white crystals (EtOH/
H2O); mp 66–68°C; ESI-MS (positive mode), m/z 503
[M + H]+. 1H and 13C NMR data were consistent with a
previous report [8].
Determination of antiestrogenic activity by Recombinant
yeast assay (RYA)
Yeast strain BY4741 (MATa ura3Δ0 leu2Δ0 his3Δ1
met15Δ0) from Euroscarf (Frankfurt, Germany), kindly
provided by Dr. Benjamin Piña (CSIC-Barcelona-Spain)
was transformed with plasmids pH5HE0 and pVitBX2, as
described elsewhere [21]. The expression plasmid pH5HE0
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tive yeast vector expression pAAH5. The reporter plasmid
p VitBX2 contains two copies of the pseudopalindromic
estrogen responsive element ERE2 from Xenopus laevis
vitellogenin B1gene (5′AGTCACTGTGACC-3′) inserted
into the unique KpnI site of pSFLΔ-178 k [23]. In brief,
transformed yeast cells were first grown overnight in
non-selective medium (YPD) at 30°C. Next, the growing
cells were transferred to minimal medium (6.7 g/L yeast ni-
trogen base without amino acids, Difco, Basel, Switzerland;
20 g/L glucose, supplemented with 0.1 g/L of prototrophic
markers as required) and incubated overnight at 30°C.
The final culture was adjusted to an optical density (OD) of
0.1 and distributed in a siliconized 96-well polypropylene
microtiter plate. Aliquots of 10 μL nemorosone solutions
in dimethyl sulfoxide (DMSO) at a concentration of 40 μg/
well were added to 90 μL of yeast culture. These initial
solutions were used for subsequent serial dilutions
(1:10, 1:30, 1:90, 1:270 and 1:810). 17-β-estradiol (E2) at a
final concentration of 10 nM was added to all these wells.
Positive controls were made by adding E2 (10 nM) to
the yeast culture without the presence of nemorosone.
Negative controls were made with pure cultures and by
adding 10 μL of DMSO on the yeast culture. A solvent
control was made by adding 10 μL of DMSO to the
yeast culture with E2. The cytotoxicity was assayed
on separate YPD agar plates on which the following
were spread: pure yeast culture; yeast culture+E2; yeast
culture+E2+nemorosone in the major concentration
(40 μg/well); yeast culture+E2+DMSO. After 24hours, tests
growth was compared to the pure yeast culture growth
(100% viability) and the nemorosone concentration which
permitted 80% viability, was used in the subsequent assays.
The 96-well plates were incubated for 6 h at 30°C with
mild shaking. After incubation, 50 μL of the yeast cell
lysis reagent Y-PERTM (PierceTM, Rockford, IL, USA) was
added to each well and further incubated at 30°C for
30 min. Finally, 50 μL of assay buffer was added to the
lysed cells. The assay buffer was prepared by mixing
100 mL Z-buffer, 1 mLTriton X-100, 1 mL 10% SDS, 70 μL
2-mercaptoethanol and 21 mg 4-methyl umbelliferyl
β- D-galactoside. Z-Buffer (pH7.0) is a mix of: 60 mM
Na2HPO4 , 40 mM NaH2PO4, 10 mM KCl and 1 mM
MgSO4. Plates were read in a spectrofluorometer (Tecan
SpectraFluor Plus), set at 355 nm excitation and with
460 nm emission, for 20 minutes, after brief centrifugation
The fluorescence induced by E2 (positive control) was
considered 100% of the estrogenic activity. The entire
assay was performed on three replicates.
Cell lines
MCF-7 BUS
Human MCF-7 BUS breast cancer cells were kindly pro-
vided by Laboratory of Medical Investigations (Departmentof Environmental Medicine; University of Granada,
Granada, Spain) and were cultured in Dulbecco’s Modified
Eagle Medium (DMEM) with 15 mg/L phenol red, 10%
fetal calf serum (FCS), 2% of 200 mM l-glutamine, 2% of
1 M HEPES buffer, 1% of 100 mM sodium pyruvate and
1% of 10 mg/mL penicillin–streptomycin, at 37°C in an
atmosphere of 5% CO2 and 95% air at saturating humidity.MCF10A
Human MCF10A non-tumorigenic breast cells were kindly
provided by Dr. Maria Mitzi Brentani of the Radiology
Department Oncology Laboratory (Faculty of Medicine,
São Paulo University, São Paulo, Brazil) and were cultured
in DMEM/Ham’s F-12 medium (Gibco, Invitrogen) supple-
mented with 100 ng/mL cholera toxin (Calbiochem, La
Jolla, CA), 0.01 mg/mL insulin (Sigma, Saint Louis, MO),
500 ng/mL hydrocortisone (Sigma), 20 ng/mL epidermal
growth factor (Sigma) and 5% horse serum (Gibco,
Invitrogen) at 37°C in an atmosphere of 5% CO2 and 95%
air under saturating humidity.Determination of estrogenic and antiestrogenic activity by
E-screen assay
The simple and sensitive E-screen cell proliferation assay
was performed with the human MCF-7 BUS breast cancer
cell line. These cells express high levels of ERα and are
considered to be the most sensitive line in existence [24].
Growth stimulation of the MCF-7 BUS by compounds,
was measured as described in [25], with modifications
by [26].
Subconfluent MCF-7 BUS cells were trypsinized and
seeded in 24-well plates at an initial density of 2 × 104
cells per well in DMEM with 10% (v/v) FCS (1 mL/well).
After cell adhesion to well bottoms (24 h of incubation;
37°C, 5% CO2), the cells were washed with phosphate
buffered saline (PBS) and the culture medium was
changed to DMEM supplemented with 10% of charcoal
dextran-stripped (steroid-free) fetal calf serum (FCS).
The steroid-free experimental medium thus consisted
of phenol-red-free DMEM supplemented with 10% of
stripped FCS, 2% of 200 mM l-glutamine, 2% of 1 M
HEPES buffer, 1% of 100 mM sodium pyruvate and 1%
of 10 mg/mL penicillin-streptomycin.
The positive and negative controls used were 10-8M E2
and steroid-free experimental medium, respectively.
There was also a solvent control (0.01% DMSO, which is
the maximum concentration of solvent used in test in
steroid-free experimental medium) and a medium control
(10% FCS in DMEM).
Nemorosone was added to the experimental medium
at a range of concentrations from 10-9 to 10-5 M. The
concentrations were selected on the basis of a preliminary
toxicity test employing the sulforhodamine B (SRB) assay
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triplicate samples.
The assay was terminated after 144 hours of incubation
by removing the medium from the wells and then the SRB
assay was conducted.
For antiestrogenicity tests, 10-8 M of E2 was added to
the wells with the nemorosone, before incubation.
The estrogenic activity results were expressed as mean
± standard deviation of the proliferative effect (PE) and
relative proliferative effect (RPE). The PE represents the
proliferation induced by the test substance in MCF-7
BUS cells. This parameter is calculated as described by
[24] being the ratio of the highest cell number achieved
with E2 or the test sample to the cell number in the
negative control:
PE ¼ absorbancecompound=absorbancenegativecontrol
The RPE compares the maximal proliferation induced
by E2 with that induced by a test compound
RPE% ¼ PE‐1ð Þ sample= PE‐1ð Þ E2ð Þ  100
The RPE classifies E2 total agonists when they induce
a relative proliferation between 80% and 100%. Partial
and weak agonists induce a cell proliferation from 25%
to 80%, and from 10% to 25%, respectively [28]. For the
calculation of these parameters, Excel (Microsoft, NY,
USA) formulae and functions were used.
Comet assay
For the comet assay, MCF-7 BUS and MCF10A cells
were seeded in 24-well plates at an initial concentration
of 2 x 104 cells per well and treated with nemorosone at
a range of concentrations from 10-9 to 10-5 M, for 3 and
24 hours. The positive and negative controls used were
methyl methanesulfonate 2 μM and experimental
medium, respectively. There was also a solvent control
(0.01% DMSO, which is the maximum concentration of
solvent used in test).
After resuspending the cells, the following steps of the
assay were carried out [29]: (I) coating of microscope
slides with normal-melting-point agarose; (II) transfer of
the treated cell suspension to a microcentrifuge tube;
(III) suspension of 20 μL of cells in 100 μL of a 0.5%
low-melting agarose solution at 37°C; (IV) pousing of
100 μL of this final suspension on the slides, which had
been kept in a freezer for 5 min. The alkaline version
of the comet assay (single cell gel electrophoresis) was
performed as described by Singh et al. [30]. Briefly,
100 μL of cells were taken, homogenized with low-melting
point agarose, spread on a microscope slide pre-coated
with normal-melting-point agarose and covered with a
coverslip. After 5 min at 4°C, the coverslip was removed
from the slides and they were immersed in cold lysingsolution (2.4 M NaCl; 100 mM ethylenediaminetetraacetic
acid (EDTA); 10mM Tris, 10% dimethylsulfoxide and 1%
Triton-X, pH 10) for 24 h. After lysis, the slides were
placed in an electrophoresis chamber, covered with
electrophoresis buffer (300 mM NaOH plus 1 mM EDTA,
pH >13) and left for 20 min for the DNA to unwind. The
electrophoresis ran for 20 min (25 V and 300 mA), after
which the slides were submerged for 15 min in a
neutralization buffer (0.4 M Tris–HCl, pH7.5) and fixed
in 96% ethanol for 5 min. Duplicate slides were stained
with ethidium bromide and 50 cells were screened per
sample in a fluorescent microscope (OLYMPUS® XM10)
equipped with an excitation filter of 515–560 nm, a barrier
filter of 590 nm and a×40 objective. The level of DNA
damage was assessed by an image analysis system (TriTek
CometScore™ 1.5, 2006) and the percentage of DNA in
the tail (%DNA) and Olive Tail Moment (OTM) were
obtained.
Statistical analysis
In the RYA assay, the fluorescence in the presence of
nemorosone was analyzed with GraphPad Prism 5.0
(GraphPad Software Inc., San Diego, CA) using the
ANOVA test followed by the Dunnet post-test in order to
detect significant inhibition of E2 induced fluorescence
after nemorosone treatment. The same statistical analysis
was used to evaluate the antiestrogenic activity by E-screen
assay, in order to detect significant inhibition of E2 induced
proliferation on MCF-7 BUS (100% proliferation) by the
nemorosone treatment. The comet assay were analyzed
with the non-parametric Kruskal-Wallis test followed by
the Dunn post-test [31] to detect significant DNA damage
induced by nemorosone in relation to negative control.
Results and discussion
A series of in vitro assays have been developed in order
to detect predominant mechanism of action of potential
estrogens. Most of these assays fall into one of three
categories: a) ER competitive binding assays that measure
the binding affinity of a chemical for the ER; b) reporter
gene assays that measure ER binding-dependent tran-
scriptional and translational activity and c) cell prolif-
eration assays that measure the rate of increase in the
number of target cells during the exponential phase of
proliferation [32].
The recombinant yeast cells were designed and engineered
for exquisite sensitivity to estrogens [33]; overexpression
of human ER, high amplitude frog vitellogenin estrogen
response elements, and their tandem arrangement in the
reporter plasmid all serve to amplify β-galactosidase pro-
duction and hence sensitivity towards E2 [34]. This assay
involves not only agonist binding to the receptor but also
receptor-mediated transcription. It can to detect the














































Figure 2 Dose/response plot for various nemorosone (NM) dilutions in presence of 17 β-estradiol (E2 10
-8M) and positive control
(100% estrogenic activity) in the RYA system. The graph shows the β-galactosidase activity in percentage (estrogenic activity) for each
nemorosone dilution, from three experiments performed in triplicate. These results are expressed as the mean±SD of three separate experiments.
Values significantly different from the E2 are indicated by an asterisk (*p<0.05 by Student’s t-tests).
Table 1 Proliferative effects (PE) and relative proliferative
effects (RPE%) of nemorosone (NM) and E2 according to
the E-screen assay
Compound Max PE Max RPE%
Positive control (E2) 3.44±0.57 100
NM 10-9M 1.02±0.01 0.8
NM 10-8M 1.09±0.08 3.82
NM 10-7M 1.03±0.02 1.07
NM 10-6M 1.05±0.03 1.87
NM 10-5M 1.10±0.08 3.94
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estrogenic compounds and E2 [35].
Our results show that nemorosone reduced significantly
the estrogenic activity induced by E2 (Figure 2). Antagonist
activity of nemorosone was detected at 3 concentrations
by this assay. The estrogenic activity of E2 was reduced
in 31%, 34% and 42% by nemorosone at 10, 20 and
40 μg/well, respectively.
The ERs agonist activity of nemorosone by RYA was
already evaluated by Camargo et al. [20] and the results
showed an absence of estrogenicity by its benzophenone.
These results show that nemorosone does not have
the capacity of binding to the ER and mediating the
transcription in an agonist away (causing the same effects
of the estradiol), but also reduces the capacity of 17 E2 to
exercise this function.
A hallmark physiological response to estrogenic stimuli
is the proliferation of cells in vivo, and this may promote
tumor growth. This cell proliferation can also be mim-
icked in vitro. The E-screen uses established cell lines
that are known to respond to estrogens and with it
measures cell proliferation in response to increasing
doses of the test compound. This assay is widely used
and acknowledged as a reliable and valid test for a
physiological response to estrogen action and can also
discriminate agonists from antagonists [36].The first step to evaluate the estrogenic activity of
nemorosone by the E-screen assay was to construct the
dose-proliferative response curve for E2 in MCF-7 BUS
cells, and use it as a reference curve. The concentrations
of 10-6M to 10-11M E2 were tested, being the 10
-8 M the
best concentration to induce cell proliferation (data not
shown).
The growth of MCF-7 BUS cells was performed in order
to ascertain the function of nemorosone as an estrogen
agonists or as an estrogen antagonists. MCF-7 BUS cells
were treated with benzophenone for 6 days, and cell growth
was measured by the SRB method [27]. The effects on the
proliferation of MCF-7 BUS cells of E2 and nemorosone
are shown in Table 1. The results are expressed as PE and



















Figure 3 Effects of nemorosone (NM) on MCF-7 BUS cell proliferation. The cells were treated with E2 (10
-8M) and nemorosone
(10-5 to 10-9M) for 144 h. The SRB assay was conducted to measure cell proliferation. The inhibition E2-induced MCF-7 BUS (100% proliferation) by
the nemorosone treatment is represented by cell proliferation in percentage. These results are expressed as the mean±SD of three separate
experiments. Values significantly different from the E2 control are indicated by an asterisk (*p<0.05 by Student’s t-tests).
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relative to E2 (10
-8M, 100%) are represented as the RPE
(Relative Proliferative Effect). The benzophenone exhibited
no estrogenic activity at any tested concentration.
The results of this assay indicated that the nemorosone
was unable to induce a significant cell proliferation by
comparison with the E2 (RPE = 100%) or more effectively
than the solvent control (DMSO 0.01%).
In order to determine whether the nemorosone in-
duced antiestrogenic activity, MCF-7 BUS cells were
treated with a combination of E2 (10
-8M) and the test
compound at various concentrations, as shown in Figure 3.Table 2 Genotoxic activity expressed by the mean and
the standard deviation (SD) of the Olive Tail Moment
(OTM) and percentage DNA in comet tail (% DNA) in
MCF-7 BUS cells treated with nemorosone for 3 and
24 hours and controls
OTM %DNA OTM %DNA
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Treatments 3 hours 24 hours
Control 1.56±2.00 8.17±6.56 1.69±3.83 3.65±7.45
DMSO 1.84±2.57 8.26±7.67 2.05±3.29 4.98±3.52
10-9M 1.23±1.88 7.75±8.32 1.52±1.92 4.47±6.00
10-8M 1.51±1.75 9.45±8.32 2.05±3.78 5.77±5.89
10-7M 1.35±1.47 6.17±7.98 2.35±1.98 6.17±5.12
10-6M 1.51±1.89 9.01±8.02 2.32±2.96 6.17±4.00
10-5M 1.11±1.73 7.67±7.98 0.94±1.60 2.48±6.76
Negative control: Culture Medium (DMEM).
DMSO: Solvent control (0.01%).The highest concentration (10-5M) reduced the cell prolif-
eration induced by E2 in 75%. Since citotoxicity was not
observed after the nemorosone treatments we suggested
that the inhibitory effects of the compound on E2-induced
cell proliferation must be related to antiestrogenic activity.
The maximum proliferative response elicited by 10-8M E2
was inhibited significantly by 10-5M nemorosone.
Nowadays, there is a wide interest in phytoestrogens
due to their potential health benefits in countering meno-
pausal symptoms and in lowering incidence of hormone-
dependent diseases including breast cancer and prostate
cancer. The anticancer properties of phytoestrogens haveTable 3 Genotoxic activity expressed by the mean and
the standard deviation (SD) of the Olive Tail Moment
(OTM) and percentage DNA in comet tail (% DNA) in
MCF10A cells treated with nemorosone for 3 and
24 hours and controls
OTM %DNA OTM %DNA
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Treatments 3 hours 24 hours
Control 1.90±2.56 9.80±10.17 1.78±2.18 10.93±4.27
DMSO 2.27±1.25 9.92±8.99 2.53±2.07 15.27±4.78
10-9M 1.95±2.42 8.10±9.17 2.27±1.50 11.78±3.16
10-8M 1.64±2.52 8.31±9.70 1.84±0.29 13.04±5.25
10-7M 1.26±1.44 7.67±5.70 1.48±0.28 10.23±7.91
10-6M 1.63±2.07 8.23±8.79 2.44±3.62 13.46±4.52
10-5M 1.58±2.14 7.76±8.31 1.83±2.40 11.38±3.87
Negative control: Culture Medium (DMEM).
DMSO: Solvent control (0.01%).
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of cell proliferation and angiogenesis [37].
Currently, the first-line agent for of ERa+breast cancer
treatment is tamoxifen, [38] a selective ER modulator
that antagonizes some in vivo effects of estrogens [39];
however, most tamoxifen-responsive breast cancer patients
become tamoxifen resistant [40]. The second-line drug
given to post-menopausal women with ERa+breast cancer
is fulvestrant (ICI 182,780), a selective ER downregulator
that completely abrogates estrogen-sensitive gene tran-
scription. However, the resistance to fulvestrant is be-
coming a concern, too [40] . The limited effectiveness
of current chemotherapeutic drugs underscores the
importance of identifying novel targeted therapies with
minimal side effects.
Nemorosone has been reported in recent years to be a
potent cytotoxic agent particularly in aggressive cancer
models characteristic for their highly chemoresistance.
More interestingly, these compounds are less cytotoxic
in normal, non-tumorigenic cells [3].
Popolo et al. [9], demonstrated that nemorosone
exerted a concentration-dependent antiproliferative
activity in MCF-7 by MTT assay. This effect seems to
involve the nemorosone/ERα interaction, since the
cytotoxic effect of nemorosone was significantly reduced by
E2, significantly enhanced by ICI 182,780 and completely
absent in MDA-MD-231 (a human breast cancer cell line
ERα–) and in LNCaP (a human prostate carcinoma cell
line ERα–/ERb+).
The majority of anticancer agents has DNA-damaging
properties and affects not only the target-cells but also
non-tumor cells. Their genotoxicity has been demonstrated
in experimental models and in cancer patients treated with
chemotherapy [41]. With the intention of in the future
using nemorosone as adjuvant in breast cancer treatment,
the comet assay was employed to evaluate DNA damage
induced by the compound. This assay is widely regarded as
a quick and reliable method of analyzing DNA damage in
individual cells [42].
DNA fragmentation (%DNA in comet tail and olive
tail moment) determined by the comet assay in the
MCF-7 BUS and MCF10A cells, that was treated for 3
and 24 hours with nemorosone (10-9 to 10-5 M), showed
no significant differences from the control cells (Tables 2
and 3). This indicates that the compound did not induce
detectable DNA damage in these cells, detectable by this
methodology.
Our results showed that nemorosone did not induce
DNA damage using this method in the concentration
range tested (10-9 to 10-5 M), neither in breast cancer
cells MCF-7 BUS or in normal breast cells. Therefore,
it is reasonable to hope that nemorosone could be a
promising adjuvant for ER antagonists in ERα + breast
cancer prevention and (or) treatment.Conclusion
The present work demonstrates that nemorosone presents
no genotoxic property and posses antiestrogenic activity,
reducing the cell proliferation induced by E2. Further
studies are required in order to establish the introduction
of nemorosone on breast cancer treatment.
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